SG11201504106XA - Therapeutic method for mesothelioma - Google Patents

Therapeutic method for mesothelioma

Info

Publication number
SG11201504106XA
SG11201504106XA SG11201504106XA SG11201504106XA SG11201504106XA SG 11201504106X A SG11201504106X A SG 11201504106XA SG 11201504106X A SG11201504106X A SG 11201504106XA SG 11201504106X A SG11201504106X A SG 11201504106XA SG 11201504106X A SG11201504106X A SG 11201504106XA
Authority
SG
Singapore
Prior art keywords
mesothelioma
therapeutic method
therapeutic
Prior art date
Application number
SG11201504106XA
Inventor
Seiji Yano
Yusuke MACHINO
Yui Suzuki
Original Assignee
Univ Kanazawa Nat Univ Corp
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kanazawa Nat Univ Corp, Kyowa Hakko Kirin Co Ltd filed Critical Univ Kanazawa Nat Univ Corp
Publication of SG11201504106XA publication Critical patent/SG11201504106XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
SG11201504106XA 2012-12-06 2013-12-04 Therapeutic method for mesothelioma SG11201504106XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734087P 2012-12-06 2012-12-06
PCT/JP2013/082621 WO2014088040A1 (en) 2012-12-06 2013-12-04 Method for treating mesothelioma

Publications (1)

Publication Number Publication Date
SG11201504106XA true SG11201504106XA (en) 2015-07-30

Family

ID=50883457

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504106XA SG11201504106XA (en) 2012-12-06 2013-12-04 Therapeutic method for mesothelioma

Country Status (7)

Country Link
US (1) US9066929B2 (en)
EP (1) EP2929895A4 (en)
JP (1) JP6310397B2 (en)
KR (1) KR20150090107A (en)
CN (1) CN105025923B (en)
SG (1) SG11201504106XA (en)
WO (1) WO2014088040A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116874608A (en) * 2017-03-27 2023-10-13 诺伊尓免疫生物科技株式会社 Chimeric antigen receptor
CN108421038A (en) * 2017-04-19 2018-08-21 范兴龙 A method of treat malignant pleural mesothelioma based on microRNA

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150991B2 (en) 1991-04-10 2001-03-26 協和醗酵工業株式会社 Hybridoma production method
JPH0651541A (en) 1992-08-03 1994-02-25 Fuji Photo Film Co Ltd Electrophotographic sensitive body
US6042828A (en) * 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5939532A (en) 1993-09-07 1999-08-17 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies to ganglioside GM2
US5830470A (en) 1992-09-07 1998-11-03 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
JP4550947B2 (en) 1997-03-19 2010-09-22 協和発酵キリン株式会社 Human complementarity determining region (CDR) grafted antibody against ganglioside GM2
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (en) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of immunofunctional molecules
BR0114475A (en) 2000-10-06 2003-12-23 Kyowa Hakko Kogyo Kk Cell for the production of antibody composition
US7935338B2 (en) 2001-12-11 2011-05-03 University Of Massachusetts Antibodies to treat cancer
EP1467755A1 (en) * 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2548787A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Antibody composition specifically binding to ganglioside gm2
ES2392824T3 (en) 2003-10-17 2012-12-14 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent against mesothelioma
UA86605C2 (en) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Antibody comprising a variant fc region
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US20070172476A1 (en) 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
WO2008090960A1 (en) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2010018846A1 (en) 2008-08-13 2010-02-18 協和発酵キリン株式会社 Drug containing antibody composition specifically binding to ganglioside gm2

Also Published As

Publication number Publication date
WO2014088040A1 (en) 2014-06-12
US9066929B2 (en) 2015-06-30
US20140220003A1 (en) 2014-08-07
JPWO2014088040A1 (en) 2017-01-05
EP2929895A1 (en) 2015-10-14
KR20150090107A (en) 2015-08-05
EP2929895A4 (en) 2016-07-20
JP6310397B2 (en) 2018-04-11
CN105025923A (en) 2015-11-04
CN105025923B (en) 2018-03-27

Similar Documents

Publication Publication Date Title
ZA201501833B (en) Method for obtaining 1-kestone
GB201223172D0 (en) Method
GB201212937D0 (en) Method
GB201212932D0 (en) Method
PL2817775T3 (en) Audience-measuring method
GB201213636D0 (en) Method
GB201212934D0 (en) Method
GB201210858D0 (en) Method
SG11201500746YA (en) System and method for geothentication
SG11201407032WA (en) Method
PL2809816T3 (en) Expression method
GB201218570D0 (en) Method
EP2880048A4 (en) Method
GB201202198D0 (en) Method
EP2907817A4 (en) Method for preparing cu-btc and nano-cu-btc
GB201211393D0 (en) Method
SG11201504106XA (en) Therapeutic method for mesothelioma
ZA201407215B (en) Method for emulsion treatment
GB201223316D0 (en) Method
GB201222737D0 (en) Method
GB201217688D0 (en) Method
GB201214029D0 (en) method
GB201210147D0 (en) Method
HK1206815A1 (en) Selection method for therapeutic agents
GB201213858D0 (en) Method